Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID

Trial Profile

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bezisterim (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms ADdRESs-LC
  • Sponsors BioVie

Most Recent Events

  • 15 May 2025 According to the BioVie Media Release, The Phase 2 ADDRESS-LC study is fully funded by a grant from the U.S. Department of Defense (DOD)
  • 15 May 2025 According to the BioVie Media Release, company announced that the first patient has been enrollment in the Phase 2 ADDRESS-LC clinical trial. The Company anticipates topline data to be available in the first half of 2026.
  • 22 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top